SEC Form 4 · accession 0000925421-17-000358
Krystal Biotech, Inc. · KRYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Krish S Krishnan
Officer — President and CEO · Director · 10% Owner
Period of report
Sep 22, 2017
Accepted (ET)
Sep 25, 2017 · 5:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001711279
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 22, 2017 | P | 100,000 | $10.00 | A | 1,935,249 | D | |
| Common StockF1,F2 | Sep 22, 2017 | C | 112,162 | — | A | 112,162 | I | By trust |
| Common StockF3 | holding | — | — | — | 1,935,249 | I | By spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Convertible Preferred StockF2,F1 | — | Sep 22, 2017 | C | 112,162 | D | — | — | Common Stock | 112,162 | 0 | I |
Explanation of responses
- F1The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering.
- F2Directly beneficially owned by the Krishnan Family Trust. The reporting person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.
- F3Directly beneficially owned by Suma M. Krishnan, the spouse of the reporting person.